Author: Jennifer C. King, PhD, Chief Scientific Officer

GO2 for Lung Cancer has launched the SPARK Study to help understand cancer driven by changes in the KRAS gene. This study is through our medical research consortium, ALCMI (Addario Lung Cancer Medical Institute), in collaboration with Dr. Mark Award and team at Dana Farber Cancer Institute and colleagues at Foundation Medicine.  

About the SPARK Study

Any person, anywhere in the United States, who has had lung cancer that has been treated with a KRAS inhibitor (such as Lumakras (sotorasib) or Krazati (adagrasib)) can take part in the trial if the cancer begins to recur after taking one of those therapies. All it takes to participate is a blood draw at home or through a local provider. You do not have to change doctors, have a biopsy or travel.   

The blood is sequenced at Foundation Medicine and the reports are analyzed by Dr. Awad’s team to understand the patterns of how cancer can progress on these new drugs. A copy of the report will also be given to study participants and their oncologists in case it is helpful for making treatment decisions.  

Hope for the KRAS Community

KRAS was thought to be untargetable for decades–until these two drugs were approved in 2021 and 2022. Now, we are just starting to learn why and how some cancers can progress after treatment with these therapies.  

“The SPARK Study will lead to a deeper understanding about how to anticipate and overcome KRAS G12C drug resistance. This crucial research provides potential next steps in treatment options for those with a KRAS-driven cancer, and this gives us hope for the future,” said Terri Conneran, lung cancer survivor and founder of KRAS Kickers, a global patient advocacy organization devoted to KRAS mutated cancers. 

If you are interested in learning more about participating in this study, you can find more information on the ALCMI website.